WHO International Standard for anti-SARS-CoV-2 immunoglobulin
- PMID: 33770519
- PMCID: PMC7987302
- DOI: 10.1016/S0140-6736(21)00527-4
WHO International Standard for anti-SARS-CoV-2 immunoglobulin
Conflict of interest statement
We declare no competing interests.
Similar articles
-
WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic.Nature. 2021 Jun;594(7862):161-162. doi: 10.1038/d41586-021-01497-8. Nature. 2021. PMID: 34089030 No abstract available.
-
Antibody tests for identification of current and past infection with SARS-CoV-2.Cochrane Database Syst Rev. 2020 Jun 25;6(6):CD013652. doi: 10.1002/14651858.CD013652. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2022 Nov 17;11:CD013652. doi: 10.1002/14651858.CD013652.pub2. PMID: 32584464 Free PMC article. Updated.
-
Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.PLoS One. 2022 Feb 7;17(2):e0262922. doi: 10.1371/journal.pone.0262922. eCollection 2022. PLoS One. 2022. PMID: 35130298 Free PMC article.
-
The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays.Int Immunopharmacol. 2021 Nov;100:108095. doi: 10.1016/j.intimp.2021.108095. Epub 2021 Aug 30. Int Immunopharmacol. 2021. PMID: 34619529 Free PMC article.
-
The importance of using WHO International Standards to harmonise SARS-CoV-2 serological assays.Lancet Microbe. 2024 Mar;5(3):e301-e305. doi: 10.1016/S2666-5247(23)00258-6. Epub 2024 Jan 12. Lancet Microbe. 2024. PMID: 38224703 Free PMC article. Review.
Cited by
-
Antigen-Specific CD4+ T-Cell Activation in Primary Antibody Deficiency After BNT162b2 mRNA COVID-19 Vaccination.Front Immunol. 2022 Feb 14;13:827048. doi: 10.3389/fimmu.2022.827048. eCollection 2022. Front Immunol. 2022. PMID: 35237272 Free PMC article.
-
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.Vaccine. 2022 Jun 9;40(26):3655-3663. doi: 10.1016/j.vaccine.2022.05.007. Epub 2022 May 8. Vaccine. 2022. PMID: 35568591 Free PMC article.
-
Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.Vaccine. 2022 Jul 29;40(31):4231-4241. doi: 10.1016/j.vaccine.2022.05.081. Epub 2022 Jun 6. Vaccine. 2022. PMID: 35691872 Free PMC article.
-
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.Science. 2022 Jan 7;375(6576):43-50. doi: 10.1126/science.abm3425. Epub 2021 Nov 23. Science. 2022. PMID: 34812653 Free PMC article.
-
Harmonization of Multiple SARS-CoV-2 Reference Materials Using the WHO IS (NIBSC 20/136): Results and Implications.Front Microbiol. 2022 May 30;13:893801. doi: 10.3389/fmicb.2022.893801. eCollection 2022. Front Microbiol. 2022. PMID: 35707164 Free PMC article.
References
-
- Le TT, Cramer JP, Chen R, Mayhew S. Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19:667–668. - PubMed
-
- WHO First WHO International Standard for anti-SARS-CoV-2 immunoglobulin. 2021. https://www.who.int/groups/expert-committee-on-biological-standardization - PMC - PubMed
-
- Coalition for Epidemic Preparedness Innovations CEPI establishes global network of laboratories to centralise assessment of COVID-19 vaccine candidates. Oct 2, 2020. https://cepi.net/news_cepi/cepi-establishes-global-network-of-laboratori...
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous